| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EW | Common Stock | Award | $0 | +3,775 | +14% | $0.000000 | 31,344 | 03 May 2022 | Direct | F1 |
| transaction | EW | Common Stock | Options Exercise | $509,184 | +23,400 | +75% | $21.76 | 54,744 | 04 May 2022 | Direct | F2 |
| transaction | EW | Common Stock | Tax liability | $52,223 | -493 | -0.9% | $105.93 | 54,251 | 04 May 2022 | Direct | |
| transaction | EW | Common Stock | Sale | $401,916 | -3,796 | -7% | $105.88 | 50,455 | 04 May 2022 | Direct | F2, F3 |
| transaction | EW | Common Stock | Sale | $953,739 | -9,155 | -18% | $104.18 | 41,300 | 04 May 2022 | Direct | F2, F4 |
| transaction | EW | Common Stock | Sale | $1,098,173 | -10,449 | -25% | $105.10 | 30,851 | 04 May 2022 | Direct | F2, F5 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EW | Employee Stock Option (Right to Acquire) | Award | $0 | +30,600 | $0.000000 | 30,600 | 03 May 2022 | Common Stock | 30,600 | $105.93 | Direct | F6 | |
| transaction | EW | Performance Rights | Award | $0 | +4,725 | $0.000000 | 4,725 | 03 May 2022 | Common Stock | 4,725 | Direct | F7 | ||
| transaction | EW | Employee Stock Option (Right to Acquire) | Options Exercise | $0 | -23,400 | -100% | $0.000000* | 0 | 04 May 2022 | Common Stock | 23,400 | $21.76 | Direct |
| Id | Content |
|---|---|
| F1 | These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| F2 | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021. |
| F3 | This transaction was executed in multiple trades at prices ranging from $105.77 to $105.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| F4 | This transaction was executed in multiple trades at prices ranging from $103.77 to $104.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| F5 | This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| F6 | These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| F7 | Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and scheduled to vest on May 3, 2025. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. |
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.